241 related articles for article (PubMed ID: 22688761)
21. Tracking Modified Vaccinia Virus Ankara in the Chicken Embryo: In Vivo Tropism and Pathogenesis of Egg Infections.
Langenmayer MC; Lülf-Averhoff AT; Adam-Neumair S; Sutter G; Volz A
Viruses; 2018 Aug; 10(9):. PubMed ID: 30149505
[TBL] [Abstract][Full Text] [Related]
22. Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain.
Suter M; Meisinger-Henschel C; Tzatzaris M; Hülsemann V; Lukassen S; Wulff NH; Hausmann J; Howley P; Chaplin P
Vaccine; 2009 Dec; 27(52):7442-50. PubMed ID: 19539582
[TBL] [Abstract][Full Text] [Related]
23. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.
Bejon P; Peshu N; Gilbert SC; Lowe BS; Molyneux CS; Forsdyke J; Lang T; Hill AV; Marsh K
Clin Infect Dis; 2006 Apr; 42(8):1102-10. PubMed ID: 16575727
[TBL] [Abstract][Full Text] [Related]
24. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
25. Isolation of vaccinia MVA recombinants using the viral F13L gene as the selective marker.
Sánchez-Puig JM; Blasco R
Biotechniques; 2005 Nov; 39(5):665-6, 668, 670 passim. PubMed ID: 16312215
[TBL] [Abstract][Full Text] [Related]
26. Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies.
Weyer J; Rupprecht CE; Mans J; Viljoen GJ; Nel LH
Vaccine; 2007 May; 25(21):4213-22. PubMed ID: 17434244
[TBL] [Abstract][Full Text] [Related]
27. A flow cytometry-based immuno-titration assay for rapid and accurate titer determination of modified vaccinia Ankara virus vectors.
Li Z; Ling L; Liu X; Laus R; Delcayre A
J Virol Methods; 2010 Oct; 169(1):87-94. PubMed ID: 20637240
[TBL] [Abstract][Full Text] [Related]
28. Generation and Production of Modified Vaccinia Virus Ankara (MVA) as a Vaccine Vector.
Pavot V; Sebastian S; Turner AV; Matthews J; Gilbert SC
Methods Mol Biol; 2017; 1581():97-119. PubMed ID: 28374245
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of replication-deficient vaccinia virus/T7 RNA polymerase hybrid expression: effect of T7 RNA polymerase levels and alpha-amanitin.
Engleka KA; Lewis EW; Howard BH
Virology; 1998 Apr; 243(2):331-9. PubMed ID: 9568032
[TBL] [Abstract][Full Text] [Related]
30. Joint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene.
Soprana E; Panigada M; Knauf M; Radaelli A; Vigevani L; Palini A; Villa C; Malnati M; Cassina G; Kurth R; Norley S; Siccardi AG
J Virol Methods; 2011 Jun; 174(1-2):22-8. PubMed ID: 21419167
[TBL] [Abstract][Full Text] [Related]
31. Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome.
Cottingham MG; Gilbert SC
J Virol Methods; 2010 Sep; 168(1-2):233-6. PubMed ID: 20417665
[TBL] [Abstract][Full Text] [Related]
32. Transient and inducible expression of vaccinia/T7 recombinant viruses.
Mohamed MR; Niles EG
Methods Mol Biol; 2004; 269():41-50. PubMed ID: 15114006
[TBL] [Abstract][Full Text] [Related]
33. Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination.
Verheust C; Goossens M; Pauwels K; Breyer D
Vaccine; 2012 Mar; 30(16):2623-32. PubMed ID: 22342706
[TBL] [Abstract][Full Text] [Related]
34. Generation of recombinant vaccinia viruses.
Earl PL; Moss B; Wyatt LS; Carroll MW
Curr Protoc Protein Sci; 2001 May; Chapter 5():Unit5.13. PubMed ID: 18429179
[TBL] [Abstract][Full Text] [Related]
35. Preparation of Cell Cultures and Vaccinia Virus Stocks.
Cotter CA; Earl PL; Wyatt LS; Moss B
Curr Protoc Microbiol; 2015 Nov; 39():14A.3.1-14A.3.18. PubMed ID: 26528781
[TBL] [Abstract][Full Text] [Related]
36. Transient host range selection for genetic engineering of modified vaccinia virus Ankara.
Staib C; Drexler I; Ohlmann M; Wintersperger S; Erfle V; Sutter G
Biotechniques; 2000 Jun; 28(6):1137-42, 1144-6, 1148. PubMed ID: 10868279
[TBL] [Abstract][Full Text] [Related]
37. Recombinant viruses obtained from co-infection in vitro with a live vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus display different plaque phenotypes and loss of the transgene.
Hansen H; Okeke MI; Nilssen O; Traavik T
Vaccine; 2004 Dec; 23(4):499-506. PubMed ID: 15530698
[TBL] [Abstract][Full Text] [Related]
38. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.
Rimmelzwaan GF; Sutter G
Expert Rev Vaccines; 2009 Apr; 8(4):447-54. PubMed ID: 19348560
[TBL] [Abstract][Full Text] [Related]
39. Enveloped virus is the major virus form produced during productive infection with the modified vaccinia virus Ankara strain.
Spehner D; Drillien R; Proamer F; Houssais-Pêcheur C; Zanta MA; Geist M; Dott K; Balloul JM
Virology; 2000 Jul; 273(1):9-15. PubMed ID: 10891402
[TBL] [Abstract][Full Text] [Related]
40. [Construction and the immunogenicity of the recombinant Modified Vaccinia Virus Ankala co-expressing ORF4, ORF5 and ORF6 genes of porcine reproductive and Respiratory Syndrome Virus NJ-a strain].
Zheng QS; Bi ZX; Li P; Chen DS; Chen PY
Wei Sheng Wu Xue Bao; 2007 Apr; 47(2):345-9. PubMed ID: 17552247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
